Lyra Therapeutics Competitors and Similar CompaniesClear all
Lyra Therapeutics's competitors and similar companies include Intersect ENT, Acorda Therapeutics, Codiak Biosciences and Spur Therapeutics.
 Lyra Therapeutics Lyra Therapeutics is a therapeutics company focused on the development of integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. |  Intersect ENT Intersect ENT (also known as Medtronic Ear, Nose & Throat) is an ear, nose, and throat medical technology company. |  Acorda Therapeutics Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. |  Codiak Biosciences Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. |  Spur Therapeutics Spur Therapeutics (formerly known as Freeline) is a clinical-stage biotechnology company that develops transformative gene therapies. | |
Founding Date | Founding Date 2005 | Founding Date 2003 | Founding Date 1995 | Founding Date 2015 | Founding Date 2015 |
Type | Type Public | Type Subsidiary | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Watertown, US HQ | Locations Menlo Park, US HQ | Locations Ardsley, US HQ Chelsea, US South San Francisco, US Waltham, US | Locations Cambridge, US HQ | Locations Stevenage, GB HQ Boston, US New York, US |
Employees | Employees 34 | Employees 4337% increase | Employees 4742% decrease | Employees 992% decrease | Employees 122 |
Valuation ($) | Valuation ($) 17.4 m | Valuation ($) N/A | Valuation ($) 821 k | Valuation ($) 2.8 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $398k (FY, 2025) | Revenue (est.) $106.7m (FY, 2021) | Revenue (est.) $117.6m (FY, 2023) | Revenue (est.) $22.9m (FY, 2021) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $30m (FY, 2021) | Cost of goods $15.3m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $76.7m (FY, 2021) | Gross profit N/A | Gross profit N/A | Gross profit $8.9m (FY, 2022) |
Net income | Net income ($28.9m) (FY, 2025) | Net income ($159.6m) (FY, 2021) | Net income ($252.9m) (FY, 2023) | Net income ($37.2m) (FY, 2021) | Net income ($89m) (FY, 2022) |
Operating ⚠ | |||||
Products | Products N/A | Products 2 (FY, 2016) | Products N/A | Products 11 (Q2, 2020) | Products N/A |
Trademarks | Trademarks N/A | Trademarks 29 (FY, 2016) | Trademarks N/A | Trademarks N/A | Trademarks 14 (May, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 59.5m | Total funding raised $ 102.9m | Total funding raised N/A | Total funding raised $ 168.5m | Total funding raised $ 289.3m |
For sources of this data, please see the company profile
View Company Profiles
Intersect ENT
HQ
Menlo Park, US
Intersect ENT (also known as Medtronic Ear, Nose & Throat) is an ear, nose, and throat medical technology company.
View companyAcorda Therapeutics
HQ
Ardsley, US
Employees
474↓ 2% decrease
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
View companyCodiak Biosciences
HQ
Cambridge, US
Employees
99↓ 2% decrease
Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics.
View companySpur Therapeutics
HQ
Stevenage, GB
Spur Therapeutics (formerly known as Freeline) is a clinical-stage biotechnology company that develops transformative gene therapies.
View company